EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Skin Permeation of 5-Fluorouracil through Drug-in-Adhesive Topical Patches

Sangseo Kim iD, Souha H Youssef iD, Kyung Min Kirsten Lee, Yunmei Song iD, Sachin Vaidya, Sanjay Garg iD

Pharmaceutics · 10.03.2024 · 16 (3) · 379

DOI: 10.3390/pharmaceutics16030379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 10.03.2024. Verfasst von Sangseo Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

5-fluorouracil (5-FU), commercially available as a topical product, is approved for non-melanoma skin cancer (NMSC) treatment with several clinical limitations. This work aimed to develop 5-FU-loaded topical patches as a potential alternative to overcome such drawbacks. The patches offer accurate dosing, controlled drug release and improved patient compliance. Our study highlights the development of Eudragit® E (EuE)-based drug-in-adhesive (DIA) patches containing a clinically significant high level of 5-FU (approximately 450 µg/cm2) formulated with various chemical permeation enhancers. The patches containing Transcutol® (Patch-TRAN) or oleic acid (Patch-OA) demonstrated significantly higher skin penetration ex vivo than their control counterpart, reaching 5-FU concentrations of 76.39 ± 27.7 µg/cm2 and 82.56 ± 8.2 µg/cm2, respectively. Furthermore, the findings from in vitro permeation studies also validated the superior skin permeation of 5-FU achieved by Patch-OA and Patch-TRAN over 72 h. Moreover, the EuE-based DIA patch platform demonstrated suitable adhesive and mechanical properties with an excellent safety profile evaluated through an inaugural in vivo human study involving 11 healthy volunteers. In conclusion, the DIA patches could be a novel alternative option for NMSC as the patches effectively deliver 5-FU into the dermis layer and receptor compartment ex vivo for an extended period with excellent mechanical and safety profiles.

Schlagwörter

Stichwörter der Autor:innen

5-fluorouracilEudragit® EStrat-M® membranechemical permeation enhancersdrug-in-adhesive patchesnon-melanoma skin cancer

Autor:innen und Institutionen

  • Centre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
  • Central Adelaide Local Health Network, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia.

ORCID-Profile: Sangseo Kim, Souha H Youssef, Yunmei Song, Sanjay Garg

Zitieren

APA

Kim, S., Youssef, S. H., Lee, K. M. K., Song, Y., Vaidya, S., & Garg, S. (2024). Enhanced Skin Permeation of 5-Fluorouracil through Drug-in-Adhesive Topical Patches. Pharmaceutics, 16(3), 379. https://doi.org/10.3390/pharmaceutics16030379

Vancouver

Kim S, Youssef SH, Lee KMK, Song Y, Vaidya S, Garg S. Enhanced Skin Permeation of 5-Fluorouracil through Drug-in-Adhesive Topical Patches. Pharmaceutics. 2024;16(3):379. doi:10.3390/pharmaceutics16030379

BibTeX
@article{Kim2024,
  author = {Kim, Sangseo and Youssef, Souha H and Lee, Kyung Min Kirsten and Song, Yunmei and Vaidya, Sachin and Garg, Sanjay},
  title = {Enhanced Skin Permeation of 5-Fluorouracil through Drug-in-Adhesive Topical Patches},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {3},
  pages = {379},
  doi = {10.3390/pharmaceutics16030379}
}
Kostenlos starten →